Back
Halozyme Therapeutics 10K Form
Sell
48
HALO
Halozyme Therapeutics
Last Price:
$48.93
Seasonality Move:
2.59%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-07 | 10Q | HALO/Halozyme Therapeutics Quarterly |
| 2023-11-06 | 10Q | HALO/Halozyme Therapeutics Quarterly |
| 2023-08-08 | 10Q | HALO/Halozyme Therapeutics Quarterly |
| 2023-05-09 | 10Q | HALO/Halozyme Therapeutics Quarterly |
| 2022-11-08 | 10Q | HALO/Halozyme Therapeutics Quarterly |
| 2022-08-09 | 10Q | HALO/Halozyme Therapeutics Quarterly |
Receive HALO News And Ratings
See the #1 stock for the next 7 days that we like better than HALO
HALO Financial Statistics
Sales & Book Value
| Annual Sales: | $1B |
|---|---|
| Cash Flow: | $153.3M |
| Price / Cash Flow: | 12.45 |
| Annual Sales: | $3.92 |
| Price / Book: | 12.24 |
Profitability
| EPS (TTM): | 3.76000 |
|---|---|
| Net Income (TTM): | $485.4M |
| Gross Margin: | $855.9M |
| Return on Equity: | 137.42% |
| Return on Assets: | 23.82% |
Halozyme Therapeutics Earnings Forecast
Key Halozyme Therapeutics Financial Ratios
-
The Gross Profit Margin over the past 24 years for HALO is 84.30%.
-
The Selling, General & Administrative Expenses for HALO have been equal to 15.20% of Gross Profit Margin.
-
The Research & Development expenses have been 7.79% of Revenue.
-
The Interest Expense is 4.07% of Operating Income.
-
The Net Earning history of HALO is 43.74% of Total Revenues.
-
Per Share Earnings over the last 24 years have been positive in 12 years.
Halozyme Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | HALO |
| CUSIP: | 40637H |
| Website: | halozyme.com |
Debt
| Debt-to-Equity Ratio: | 3.13 |
|---|---|
| Current Ratio: | 8.39 |
| Quick Ratio: | 7 |
Price-to-Earnings
| Trailing P/E Ratio: | 13.97 |
|---|---|
| Forward P/E Ratio: | 7.38 |
HALO Technical Analysis vs Fundamental Analysis
Sell
48
Halozyme Therapeutics (HALO)
is a Sell
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a SellThe current Halozyme Therapeutics [HALO] share price is $47.91. The Score for HALO is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.